pharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.

Similar documents
New drugs necessity for therapeutic drug monitoring

PHARMACOKINETICS SMALL GROUP II:

PHA 5128 Spring 2000 Final Exam

CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE

PHA Case Studies V (Answers)

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Name: UFID: PHA Exam 2. Spring 2013

Pharmacokinetic parameters: Halflife

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

PHA Spring First Exam. 8 Aminoglycosides (5 points)

TDM of Aminoglycoside Antibiotics

ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN

LD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)

TDM. Measurement techniques used to determine cyclosporine level include:

PHA 5128 Case Study 4 (Answers) Total Cp = Unbound Cp/fu.

Basic Concepts of TDM

Adult Institutional Pharmacokinetics Protocol

Bassett Healthcare Clinical Laboratory

Use ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:

PHA 5128 Spring 2009 First Exam (Version B)

Carbamazepine has a clearance of L/h/kg for monotherapy. For immediate release carbamazepine, the oral bioavailbility is 0.8

Thus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.

D DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2

TDM. Generally, hepatic clearance is determined by three main factors: These three factors can be employed in the following equation:

. Although there is a little

A Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients

AMINOGLYCOSIDES TDM D O N E B Y

TDM of Digoxin. Use of Digoxin Serum Concentrations to Alter Dosages

Policy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing

PHA5128 Dose Optimization II Case Study 3 Spring 2013

Full title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

SHC Vancomycin Dosing Guide

PHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

ICU Volume 11 - Issue 3 - Autumn Series

INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS

BIOPHARMACEUTICS and CLINICAL PHARMACY

PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS

Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Outline. How should we do TDM? Does the evidence support TDM outcomes

Approved by: SMG Origination Date: 06/14 Expiration Date: 06/17 Review Date: Revision Date: POLICY and PROCEDURE Archived Date: Page 1 of 14

Drug dosing in Extremes of Weight

Setting The setting was hospital and the economic analysis was carried out in the Netherlands.

TDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.

Comparing Methods for Once Daily Tobramycin Exposure Predictions in Children with Cystic Fibrosis

PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Doses Target Concentration Intervention

OMCJH.CHEM.COLL.INF.1001 Therapeutic Drug Monitoring Guidelines

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

M O N T H E R A P E D R O R I N G. Dr Tom Hartley UTAS HLS 2014

BSWH Pharmacist Continuing Education PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin

Aminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive

Multiple IV Bolus Dose Administration

Target Concentration Intervention

Therapeutic drug monitoring. Department of Clinical Pharmacology, Wrocław Medical University

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Basics of TDM with example drugs

Learning Outcomes. Overall Picture. Part 1 Overview of Key Concepts of Clinical Pharmacokine2cs 4/23/14. A- Awaisu- A- Nader- CPPD

Clinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult)

SBUH Aminoglycoside Dosing Protocol

IV Vancomycin dosing and monitoring Antibiotic Guidelines. Contents. Intro

IMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE:

MEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol

Lessons from recent studies. João Gonçalves Pereira UCIP DALI

Vancomycin: Class: Antibiotic.

4WS Neurology. Table of Contents

AUSTRALIAN COLLEGE OF VETERINARY SCIENTISTS CHAPTER OF VETERINARY PHARMACOLOGY

USES OF PHARMACOKINETICS

PHA Final Exam Fall 2006

AMINOGLYCOSIDES DOSING AND MONITORING GUIDELINES

Pharmacokinetics Overview

Aminoglycosides John A. Bosso, Pharm.D.

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

The general Concepts of Pharmacokinetics

A NEW APPROACH TO THERAPEUTIC DRUG MONITORING OF TOBRAMYCIN IN CYSTIC FIBROSIS

Trust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults

PHA5128 Dose Optimization II Case Study I Spring 2013

THE AMINOGLYCOSIDE ANTIBIOTICS

ECN Protocol Book. Generic Chemotherapy Protocol Guidelines. ECN_Protocol_Book_generic chemotherapy protocol guidelines guidelines_1

Basic Principles of Therapeutic Drug Monitoring

Initiating Aminoglycosides Safely. Last updated: July 2016, Version 5 Questions/Comments?

PHARMACOKINETIC PARAMETERS OF VALPROIC ACID AND CARBAMAZEPINE FROM ROUTINELY COLLECTED DATA: INFLUENCE OF PATIENT CHARACTERISTICS

Specialized Explanations for Dosage Selection

ACCP/SCCM Critical Care Preparatory Review and Recertification Course Learning Objectives

PHARMONITOR II. Optimisation of aminoglycosides dosage regimen with pharmacokinetics modeling. Pierre Wallemacq

Pharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of

Challenges of therapeutic drug monitoring in paediatrics

Clinical Safety & Effectiveness Cohort # 10

Overview on Monitoring of Therapeutic Drugs

Case Study 2 Answers Spring 2006

PPP 1. Continuation, modification, and discontinuation of a medication

PHAR 7632 Chapter 16

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO

EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING

Pharmacotherapy Issues in the Pediatric Population

Transcription:

Therapeutic drug monitoring (TDM) Is a tool that can guide the clinician to provide effective and safe drug therapy in the individual patient. Monitoring can be used to confirm a plasma drug concentration which is above or below the therapeutic range, thus minimizing the time which elapses before corrective measures can be implemented in the patient Clinical pharmacokinetics emerged as a clinical discipline in the late 1960s and early 1970s. Clinical pharmacokinetic monitoring g( (CPM) helped many pharmacists to enter the clinical arena, but the focus was more on the pharmacists and tools. With the widespread acceptance of pharmaceutical care and patient-focused pharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process. ١

According to one authority, we (pharmacists) provided CPM in the early years because pharmacy needed a mechanism to get out of the basement. CPM helped to justify our entry into the clinical arena. Likewise, according to another, many of us had the climbing the mountain because it s there mentality. Because the results of drug assays were available and we knew how to use and apply the appropriate pharmacokinetic equations, we climbed our mountain and provided CPM (TDM). WHY USE THERAPEUTIC DRUG MONITORING? The success of any fixed dosing regimen most often is based on the patient's clinical response to the drug. Fixed dosing regimens are designed to generate plasma drug concentrations (PDC) within a therapeutic range, ie, achieve the desired effect while avoiding toxicity. ٢

FOR WHICH DRUGS? Therapeutic drug monitoring (TDM) becomes important when: a) the drug has a narrow therapeutic-toxic range, b) there is a large variability in pharmacokinetic i parameter values between patients, c) the therapeutic effect is not readily assessed (e.g. antibiotics) or clinical symptoms are to be avoided (e.g. seizure). d) there is a direct relationship between Cp or concentration in other biological sample (e.g. saliva) and pharmacological effect, e) the expected or desired therapeutic effect is not observed Example Drugs Aminoglycosides such as gentamicin and tobramycin (0.5-8 mg/l) Digoxin (0.8 1.8 (???) µg/l) Phenytoin (10-20 mg/l) Theophylline (10-20 mg/l) Cyclosporine (0.15-0.4 mg/l) ٣

TDM Procedure Pharmacist and Physician develop initial dosing recommendations and target t concentrations Information required 1 Patient - age, weight, sex, height, smoker or not,.. 2 Clinical - clinical status (renal creatinine clearance, cardiac, liver, etc.) TDM Procedure contd... Calculate initial loading g( (and maintenance dose) and make recommendation Organize sample collection and analysis ٤

TDM contd... Sample Collection Accurate timing required Evaluate result pharmacokinetically Recalculate dosing regimen Organize further samples if required Population data Average values for V, Clearance etc. derived from large groups of patients. Where appropriate, these are quoted as per Kg body weight. Adjustments t may be made for characteristics such as smoking and certain disease states. Individual data Values for V, Clearance etc calculated from measured blood concentrations following the application of a known dose of the drug to the individual patient in question. ٥

New patient Determine body weight and any other relevant characteristics (Smoker, Cirrhosis, Renal failure etc) Calculate a dosage regime on basis of population data Apply this regime to the patient? Take blood samples (Therapeutic Drug Monitoring - TDM ) and note clinical state of patient If necessary, re-calculate dosage on basis of individualised data. Patient Monitoring Signs of Curing Signs of Adverse Reaction Physician Reassessment Pharmacist Modify Dosing Patient Monitoring Curing Termination of the Treatment ٦

Therapeutic failure of Phenobarbital Patient:??????? Chief Complaint: Seizures Pertinent History: Diagnosed as epileptic 6 months prior to presentation. Patient was suffering from severe cluster seizures. Response to phenobarbital was initially but 6 months into therapy, the patient has begun seizuring again. Drug of interest: Phenobarbital Dosing Regimen: 4.1 mg/kg every 12 hours orally. Duration of current regimen: 6 months. Phenobarbital concentrations at 3 months (baseline) were 35 mg/ml (peak) and 31mg/ml (trough). Elimination half-life at that time was 40 hours Recommendation: Increase phenobarbital dose to 7.5 mg/kg every 12 hours (4.5 mg/kg x 30 mg/ml / 18 mg/ml), targeting a peak concentration of 30 mg/ml. Retest at new steady-state (which will only take 3 to 5.5 days in this patient.) Follow-up: The dose was increased to 6.5 mg/kg. Drug concentrations one month later were 33 mg/ml (peak) and 29 mg/ml (trough). Patient has been seizure free for six months. Although bromide therapy could have been started in this patient, the increase in phenobarbital concentration was easier and as effective, leaving bromide available should this patient's disease get worse. ٧

Aminoglycoside and intensive fluid therapy Patient:???????? Chief Complaint: Peritonitis and bacteremia secondary to prostatic abscess Pertinent History: Surgical correction of prostatic abscess. Drug samples collected 24 hours postoperatively. Other drugs: Antiemetics (metoclopramide); intensive fluid therapy. Drug of interest: t Gentamicin i Dosing Regimen: 4 mg/kg IV every 24 hours Duration of current regimen: 24 hours Patient Response: Febrile, non-responsive Drug elimination half-life: 2.4 hrs Volume of distribution: 0.45 l/kg Predicted Peak concentration: 10 mg/ml Trough Concentration: non-detectable Recommendation: Double the dose to target 20 mg/ml (assuming an MIC of 1 to 2 mg/ml) and maintain current 24 hour dosing interval. Follow-up: Patient condition remained critical for two more postoperative days but then began progressive improvement. Patient was discharged 10 days postoperatively. ٨

Advantages of TDM 1) Facilitates t rapid determination ti of of the appropriate dosing regimen. 2) Evaluates existing dosage regimen. 3) Protects against drug toxicity. 4) Distinguishes between PK and PD causes of therapeutic failure. In Gallup's annual Honesty and Ethics poll, expanded this year to include nurses and 19 additional occupations not previously rated, nearly three-quarters of Americans, 73%, deem nurses' honesty and ethics as either very high or high, putting them at the top of the list. Pharmacists remains the top-rated t profession among occupations previously measured over the past 22 years; however, with a combined high/very high rating of 69%, they trail nurses on the new, expanded list by four percentage points. These are the Top Five professions and occupations considered most honest by the American public: Nurses 73%, Pharmacists, 69% Veterinarians, 63% Medical Doctors, 58% ٩

alghazam@ju.edu.jo ١٠